Drug intelligence / Profile preview

Q-015

Development stage: Preclinical
Lead developer: Queensland Emory Drug Discovery Initiative
Modality: Small Molecules

Overview

Q-015 is a small molecule therapeutic candidate being developed by the Queensland Emory Drug Discovery Initiative (QEDDI) for the treatment of heart failure. The drug is currently in the lead optimization stage of preclinical development. Its molecular target has not been publicly disclosed.

Beyond the preview

Go deeper on Q-015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Q-015.

Explore the full profile